Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine

News   Dec 03, 2012

 
Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine
 
 
 

RELATED ARTICLES

PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug Discovery

News

Investment to fund expansion of operations and progression of drug target pipeline.

READ MORE

Stem Cell Signaling Drives Mammary Gland Development

News

New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.

READ MORE

Inflammatory Bowel Disease Linked with Common Bacterial Gut Toxin

News

New research has uncovered a surprise link between a common bacterial toxin found in the gut and inflammatory bowel disease (IBD). It shows that breakdown products from the toxin seem to trigger gut inflammation that is characteristic of IBD.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE